[Translation] A randomized, double-blind trial to evaluate the efficacy and safety of TV-44749 in adults with schizophrenia.
Blind, placebo-controlled study, including an open-label, long-term safety phase
:精神分裂症是一种使人衰弱的重度精神病性障碍,其特征包括阳性和阴性症状,全
球终生发病风险约为 1%。对于大多数患者来说,这一疾病伴有需要长期使用抗精神病药
物治疗的慢性病程。不依从和不遵守长期口服药物治疗方案是精神分裂症和相关疾病治疗
中最重要的治疗问题,导致这些患者中的许多频繁复发或加重,且无法从抗精神病药物治
疗中完全获益。缓释注射用抗精神病药物可能会提高精神分裂症患者的依从性。目前,奥
氮平的口服、长效肌肉注射 (im) 和速效 im 制剂被批准用于治疗患有精神分裂症的成人。
一种用于皮下注射 (sc) 的奥氮平缓释混悬液新制剂 (TV-44749) 旨在用于治疗精神分裂
症。
[Translation] : Schizophrenia is a debilitating, severe psychotic disorder characterized by positive and negative symptoms, all
The lifetime risk of developing the disease is approximately 1%. For most patients, the disorder is accompanied by the need for long-term use of antipsychotics
The chronic course of medical treatment. Nonadherence and failure to adhere to long-term oral medication regimens in the treatment of schizophrenia and related disorders
The most important treatment issue in the disease is that many of these patients have frequent relapses or exacerbations and are unable to respond to antipsychotic medications.
Completely benefited from treatment. Extended-release injectable antipsychotics may improve compliance in patients with schizophrenia. Currently, Austria
Oral, long-acting intramuscular (im), and rapid-acting im formulations of azapine are approved for the treatment of adults with schizophrenia.
A new formulation of olanzapine extended-release suspension (TV-44749) for subcutaneous injection (sc) intended for the treatment of schizophrenia
disease.